Idexx Laboratories price target lowered to $595 from $600 at BofA

BofA lowered the firm’s price target on Idexx Laboratories to $595 from $600 and keeps a Neutral rating on the shares. Ahead of Q1 earnings, the firm revisited some of its models and updated for recent data points and trends among its Animal Health coverage. While noting that its coverage “skews generally negative heading into the prints,” the firm adds that a number of broader market and company-specific headwinds have been reflected in the group’s marked underperformance year-to-date.